Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Waxman’s Legislative Powers On The Rise: How Much Will Fall On MedTech?

This article was originally published in The Gray Sheet

Executive Summary

Rep. Henry Waxman's new perch atop the House Energy and Commerce Committee gives the aggressive lawmaker at least as much leverage as he has recently enjoyed on the investigative front, but more authority to follow through with legislation

You may also be interested in...



House Energy and Commerce Committee subpanel chairs

Democratic Caucus of the House Energy and Commerce Committee announces subcommittee assignments for the 111 Congress, following the takeover of the chairmanship of the full committee by Rep. Henry Waxman, D-Calif., from Rep. John Dingell, D-Mich., in November ("1The Gray Sheet" Nov. 24, 2008, p. 5). Rep. Frank Pallone, D-N.J., will retain his chairmanship of the Health Subcommittee, which handles most FDA-related legislation, and Bart Stupak, D-Mich., who has been trying to persuade the incoming Obama administration to "clean house" at FDA, will retain his chairmanship of the Oversight and Investigations subpanel. Stupak sent a letter in December to the Obama transition team, asking, among other things, that no current senior FDA employee be put in charge of the agency, even on an interim basis ("2The Gray Sheet" Dec. 15, 2008, p. 23)

House Energy and Commerce Committee subpanel chairs

Democratic Caucus of the House Energy and Commerce Committee announces subcommittee assignments for the 111 Congress, following the takeover of the chairmanship of the full committee by Rep. Henry Waxman, D-Calif., from Rep. John Dingell, D-Mich., in November ("1The Gray Sheet" Nov. 24, 2008, p. 5). Rep. Frank Pallone, D-N.J., will retain his chairmanship of the Health Subcommittee, which handles most FDA-related legislation, and Bart Stupak, D-Mich., who has been trying to persuade the incoming Obama administration to "clean house" at FDA, will retain his chairmanship of the Oversight and Investigations subpanel. Stupak sent a letter in December to the Obama transition team, asking, among other things, that no current senior FDA employee be put in charge of the agency, even on an interim basis ("2The Gray Sheet" Dec. 15, 2008, p. 23)

Peace On Commerce, Good Will To Dingell

Rep. John Dingell, D-Mich., will be the lead sponsor of national health care legislation emanating from the House Energy and Commerce Committee in the 111 Congress that begins Jan. 6

Related Content

UsernamePublicRestriction

Register

MT026831

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel